Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.
about
Multiple myeloma cancer stem cellsCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategiesDevelopment of Novel Immunotherapies for Multiple MyelomaDeazaneplanocin a is a promising drug to kill multiple myeloma cells in their nicheCancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myelomaDifferentiation stage of myeloma plasma cells: biological and clinical significance.Implications of heterogeneity in multiple myeloma.Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathwayPhenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesNOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.Making Better Chimeric Antigen Receptors for Adoptive T-cell TherapyClonogenic multiple myeloma cells have shared stemness signature associated with patient survivalGrowth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit.Concise review: Defining and targeting myeloma stem cell-like cells.The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.The Tao of myeloma.Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.Phenotypic plasticity and epithelial-to-mesenchymal transition in the behaviour and therapeutic response of oral squamous cell carcinoma.Identify multiple myeloma stem cells: Utopia?Myeloma Propagating Cells, Drug Resistance and Relapse.Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma.KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.Personalization of cancer treatment using predictive simulationConcise Review: Stem Cell Population Biology: Insights from Hematopoiesis.Immunotherapies targeting CD38 in Multiple Myeloma.Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.
P2860
Q26752365-98519509-D6E1-47ED-994D-CD915826D799Q26785497-53CC66C3-B8F1-4E84-BDD7-417D53E879E7Q27302313-0AA74BDA-F9BE-4EEE-B0CB-7DBBDEB41359Q28066890-6ECACE49-AA2B-459D-A44C-E6EFF21C3F34Q28543228-3F9B1A29-125F-458B-8D24-00022B2AEB27Q28648164-FD797818-740E-4332-888D-F50B89C281F5Q33712516-079A1072-A49E-4918-8139-5ED1BBBE08A1Q33914824-23000EA9-B85F-4CE9-ACA1-DAB0B5B7DC64Q34683987-93304396-B983-4755-BBB9-C3E3B3C8E6EDQ34898664-7864D1B0-E224-480B-BD95-A4E5184F694FQ35128148-7E622A26-90A4-4AB7-8290-09F34C9B9E02Q35175289-B75D2C64-ADB7-4FF9-B7EE-751F9B97D274Q35886785-2EEA032D-74AA-4800-BA9B-600C5DCB1C22Q36830759-92BE7F3F-377D-435D-8A4D-584E97C9B831Q37207661-010A5DD1-618C-4C15-A376-2CAD4EBFA06DQ37535244-AEC7DDBB-9188-487B-8212-7F512F6A7A50Q37552008-AD4F0B0F-E79D-48DB-9CB0-D6DD72AF7508Q37684348-A9C1B961-6187-4956-B988-0D58260DC935Q38124065-98D1C7C4-405F-4756-8FB4-C8788085E329Q38151195-50770C1A-48CB-4209-B438-A8F7D572E252Q38175395-0D565D0B-4ABA-4272-8AB6-487E81E11ABBQ38180656-8CC375C3-FE22-4438-8DD7-B55348358F71Q38192044-3BA11C1C-F45A-4C9D-BEF2-FA7FF841EBEAQ38237360-62C29A7A-B8DA-4587-921F-FB8F759B21CDQ38258197-3FCBBAF6-1AB2-44F9-9F76-2DE3B889CDC0Q38320920-73B83D10-25D6-4D01-A5F3-377F7C5AEE03Q38332486-31307F28-BE81-4D68-ACCD-DFD99DC36299Q38572771-7790A5FF-7B22-4ADD-804E-FF19AEC04258Q38704573-95DFAA53-B4A0-499D-B122-06CA0ABC610EQ38764944-460FFEE2-F560-4BCB-9427-DE92FF1E47A9Q38778519-8F7A475F-2244-41A8-ADEF-D2465770E1C3Q38828754-3067D507-61A0-454A-8BB4-BF2F1747CE4EQ38860336-8B616EA8-6750-49F7-A0A0-3A15DA47326EQ38895512-3967BAA5-8174-47F3-B353-64BAB81D8B16Q38910971-6B7F3FD8-5DD3-4981-9D41-508738BCAACDQ38914605-6C8A86E9-4489-4130-B6DA-20E04020F524Q38965156-CAC96DE2-C4F9-47AB-A3D4-221B47DCBEBAQ39045031-E84A2A89-24E0-4ADE-AA98-2687337005F7Q39078376-3E6AEA2F-C701-4FC7-A52F-7310B274816FQ39389614-14997D3B-64F8-4586-B24B-5955FD5B8CB6
P2860
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Clinical drug resistance linke ...... ing cells in multiple myeloma.
@en
Clinical drug resistance linke ...... ing cells in multiple myeloma.
@nl
type
label
Clinical drug resistance linke ...... ing cells in multiple myeloma.
@en
Clinical drug resistance linke ...... ing cells in multiple myeloma.
@nl
prefLabel
Clinical drug resistance linke ...... ing cells in multiple myeloma.
@en
Clinical drug resistance linke ...... ing cells in multiple myeloma.
@nl
P2093
P50
P1433
P1476
Clinical drug resistance linke ...... ing cells in multiple myeloma.
@en
P2093
Alistair Reid
Amin Rahemtulla
Anastasios Karadimitris
Aristeidis Chaidos
Evangelos Terpos
Evdoxia Hatjiharissi
Gillian Cowan
Helen Doolittle
Helen Yarranton
Irene Roberts
P304
P356
10.1182/BLOOD-2012-06-436220
P407
P577
2012-11-20T00:00:00Z